Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis

Journal of Surgical Oncology

Volumn 99, Issue 1, 2009, Pages 9-15

  Pelz, Joerg O W ^a   Stojadinovic, Alexander ^b   Nissan, Aviram ^c   Hohenberger, Werner ^a   Esquivel, Jesus ^d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d ST AGNES HOSPITAL   (United States)

Author keywords

Carcinomatosis; Colon cancer; Peritoneal surface malignancy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOSIS; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME; ADENOCARCINOMA; COLON TUMOR; HOSPITALIZATION; HYPERTHERMIC THERAPY; INFUSION; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 58149378866     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21169     Document Type: Article

References (40)

1. Chu DZ, Lang NP, Thompson C, et al.: Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer; 1989;63:364-367.
2. Jayne DG, Fook S, Loi C, et al.: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545-1550.
3. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
4. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
5. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
6. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
7. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
8. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-237.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
10. Colucci G, Gebbia V, Paoletti G, et al.: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
11. Goldberg RM, Sargent DJ, Morton RF, et al.: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006;24:3347-3353.
12. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:58-63.
13. Jacquet P, Vidal-Jove J, Zhu B, et al.: Peritoneal carcinomatosis from gastrointestinal malignancy: Natural history and new prospects for management. Acta Chir Belg 1994;94:191-197.
14. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284-3292.
15. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995;221:29-42.
16. Sugarbaker PH: Management of peritoneal-surface malignancy: The surgeon's role. Langenbecks Arch Surg 1999;384:576-587.
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
18. Peto R, Peto J: Asymptotically efficient rank invariant procedures. J R Stat Soc A 1972;135:185-207.
19. Cox DR: Regression models and life-tables. J R Statist Soc B 1972;34:187-220.
20. Esquivel J, Sticca R, Sugarbaker PH, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancy of colonic origin: A consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128-133.
21. Fujimura T, Yonemura Y, Fujita H, et al.: Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intraabdominal malignancies. Int Surg 1999;84:60-66.
22. Cavaliere F, Perri P, Di Filippo F, et al.: Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000;74:41-44.
23. Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis: Comparison of concomitant vs. delayed management. Dis Colon Rectum 2000;43:1341-1346.
24. Beaujard AC, Glehen O, Caillot JL, et al.: Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512-2519.
25. Culliford A, Brooks AD, Sharma S, et al.: Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8:787-795.
26. Elias D, Blot F, El Otmany A, et al.: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71-76.
27. Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001;37:979-984.
28. Cavaliere F, Perri P, Rossi CR, et al.: Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: Experience of the Italian Society of Locoregional Integrated Therapy in Oncology. Tumori 2003;89:21-23.
29. Pilati P, Mocellin S, Rossi CR, et al.: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003;10:508-513.
30. Shen P, Levine EA, Hall J, et al.: Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26-33.
31. Elias D, Pocard M: Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003;12:543-559.
32. Glehen O, Mithieux F, Osinsky D, et al.: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003;21:799-806.
33. Verwaal V, Ruth S, Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743.
34. Bijelic L, Yan TD, Sugarbaker PH: Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2007;14:2281-2288.
35. Shen P, Hawksworth J, Lovato J: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal cancer. Ann Surg Oncol 2004;11:178-186.
36. Verwaal VJ, Boot H, Aleman BMP, et al.: Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: Location, treatment, and outcome. Ann Surg Oncol 2004;11:375-379.
37. Verwaal VJ, van Tinteren H, van Ruth S, et al.: Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739-746.
38. Yan TD, Sim J, Morris DL: Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2007;14:1807-1817.
39. Gomes da Silva R, Sugarbaker P: Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Am J Coll Surg 2006;203:878-886.
40. Pilati P, Mocellin S, Rossi CR, et al.: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003;10:508-513.